AARTI DRUGS LTD

Overview

AARTI DRUGS LTD is an active pharmaceutical ingredient (API) supplier with 6 active FDA Type II Drug Master Files, covering CELECOXIB; CIPROFLOXACIN HYDROCHLORIDE; NIACIN; RALOXIFENE HYDROCHLORIDE USP; RIVASTIGMINE HYDROGEN TARTRATE; ZOLPIDEM TARTRATE.

API / Drug Master Files

AARTI DRUGS LTD holds 6 active (17 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• CELECOXIBActive2009-10-09
• RIVASTIGMINE HYDROGEN TARTRATEActive2009-07-31
• RALOXIFENE HYDROCHLORIDE USPActive2008-05-22
• NIACINActive2006-12-14
• CIPROFLOXACIN HYDROCHLORIDEActive2006-07-17
• ZOLPIDEM TARTRATEActive2006-05-16
• ROFECOXIBInactive2015-09-29
• PIOGLITAZONE HYDROCHLORIDEInactive2012-07-03
• DICLOFENAC EPOLAMINEInactive2012-04-03
• S (-) RIVASTIGMINE BASEInactive2009-04-01
• TICLOPIDINE HYDROCHLORIDEInactive2008-12-30
• HYDROXYZINE HYDROCHLORIDEInactive2008-10-06
• METFORMIN HYDROCHLORIDE USPInactive2008-02-01
• NIMESULIDEInactive2007-08-28
• LORATADINEInactive2007-04-30

Showing 15 of 17 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to AARTI DRUGS LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.